Raymond James & Associates’s Nuveen Short-Term REIT ETF NURE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q1
Sell
-12,093
Closed -$344K 4010
2022
Q4
$344K Buy
12,093
+2,419
+25% +$71.4K ﹤0.01% 3133
2022
Q3
$287K Buy
9,674
+2,112
+28% +$70.9K ﹤0.01% 3210
2022
Q2
$243K Buy
7,562
+1,129
+18% +$40.4K ﹤0.01% 3377
2022
Q1
$252K Hold
6,433
﹤0.01% 3530
2021
Q4
$262K Buy
6,433
+38
+0.6% +$1.45K ﹤0.01% 3526
2021
Q3
$226K Hold
6,395
﹤0.01% 3599
2021
Q2
$217K Buy
+6,395
New +$209K ﹤0.01% 3637

Other funds holding NURE

Raymond James & Associates's NURE Position: Q1 2023 in Review

Raymond James & Associates sold out of Nuveen Short-Term REIT ETF (NURE) in Q1 2023, closing a stake of 12,093 shares — an estimated $344K sold.

Raymond James & Associates first reported a position in NURE in Q2 2021 and held it in 7 quarters. The position peaked at $344K in Q4 2022. 33 funds tracked by Wall St. Rank hold NURE as of Q1 2023.

  • Raymond James & Associates reported no remaining Nuveen Short-Term REIT ETF position as of Q1 2023 after selling out during the quarter.
  • Raymond James & Associates sold 12,093 Nuveen Short-Term REIT ETF shares in Q1 2023, an estimated $344K.
  • Raymond James & Associates first reported a position in Nuveen Short-Term REIT ETF in Q2 2021 and held it in 7 quarters.
  • Raymond James & Associates's Nuveen Short-Term REIT ETF position peaked at $344K in Q4 2022.
  • 33 funds tracked by Wall St. Rank held Nuveen Short-Term REIT ETF as of Q1 2023.

Based on Raymond James & Associates's 13F filing for Q1 2023, filed 14 Apr 2023.